Article info
PDFCurrent controversy
Pharmacological and ethical comparisons of lung cancer medicine accessibility in Australia and New Zealand
- Correspondence to Dr Elizabeth Fenton, Bioethics Centre, University of Otago, Dunedin, New Zealand; elizabeth.fenton{at}otago.ac.nz
Citation
Pharmacological and ethical comparisons of lung cancer medicine accessibility in Australia and New Zealand
Publication history
- Received November 21, 2023
- Accepted August 14, 2024
- First published August 28, 2024.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- Identifying priority medicines policy issues for New Zealand: a general inductive study
- Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry: a protocol paper
- International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study
- Advances in systemic therapy for non-small cell lung cancer
- Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
- Republished: Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
- Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice
- Novel cancer therapies: treatments driven by tumour biology
- Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)